The Lancet Publishes Data from Protege, MacroGenics' Phase 3 Clinical Study of Teplizumab in Type 1 Diabete... (clude patients for whom treatment is beg...)

The Lancet Publishes Data from Protege, MacroGenics' Phase 3 Clinical Study of Teplizumab in Type 1 Diabetes Patients

Date:6/28/2011

clude patients for whom treatment is begun less than or equal to 6 weeks after diagnosis and in children 8 -11 years old. In the coming months, MacroGenics will be exploring possible pathways forward for continued development of teplizumab."

About Type 1 Diabetes

Type 1 diabetes is an autoimmune disease in which the body's immune system attacks and destroys the insulin-producing beta cells of the pancreas. Insulin is a hormone that is needed to convert sugar (glucose), starches and other food into energy needed for daily life. People with type 1 diabetes must take multiple injections of insulin daily or continually infuse insulin through a pump to manage their blood glucose levels.

Type 1 diabetes, previously known as juvenile diabetes, usually strikes in childhood, adolescence, or young adulthood, but lasts for a lifetime. Of the nearly 24 million Americans who have diabetes, as many as 3 million may have type 1.

About Teplizumab

Teplizumab, also called MGA031 and hOKT3-gamma1 (Ala-Ala), is a humanized, anti-CD3 monoclonal antibody. Teplizumab binds to an epitope of the CD3-epsilon chain expressed on mature T lymphocytes and, by doing so, may modulate the pathological immunologic responses underlying multiple autoimmune diseases. Specifically, teplizumab may inhibit unwanted effector T cells and enhance beneficial regulatory T cell functions, thus promoting immune tolerance. MacroGenics retains full worldwide rights to teplizumab.

About MacroGenics, Inc.

MacroGenics is a private, venture-backed biotechnology company that focuses on the discovery, development and delivery to patients of novel biologics for autoimmune disorders, cancer and infectious diseases. The company has built a fully-integrated set of capabilities in antibody-based product development which supports its innovative pipeline of clinical stage product candidates. MacroGenics' proprietary research is b
'/>"/>

SOURCE MacroGenics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4
Related medicine technology :

1. Final Published Trial Data in The Lancet Supports Safety and Effectiveness of MicroVention-Terumos HydroCoil® Embolic System for Treatment of Cerebral Aneurysms
2. QNEXA® Phase 3 Data in The Lancet Show Significant Weight Loss and Broad Improvements in Co-Morbidities
3. Results Published in The Lancet Demonstrate Superiority of XGEVA™ (Denosumab) in the Prevention of Bone Complications for Men With Bone Metastases From Advanced Prostate Cancer
4. CHAMPION Study Published in The Lancet
5. Phase III Data Published in Lancet Show Novartis Drug Zometa® Improves Overall Survival in Newly Diagnosed Multiple Myeloma Patients
6. Phase III Data Showing Improved Survival With Jevtana® (cabazitaxel) Injection in Second-Line Advanced Prostate Cancer Published in The Lancet
7. Data Published in The Lancet Compare Dabigatran Etexilate to Dose-Adjusted Warfarin Across RE-LY® Trial Centers
8. Orexigen® Therapeutics Announces Publication of COR-I Phase 3 Study of Contrave in Lancet
9. Boehringer Ingelheim Affirms Safety of Telmisartan With an Analysis of 50,000 Patients and Strongly Disagrees With the Publication of Sipahi et al in Lancet Oncology June 2010
10. The Lancet publishes new data demonstrating superior efficacy of Victoza(R) (liraglutide [rDNA] injection) compared to Januvia(R) (sitagliptin) in the treatment of type 2 diabetes
11. Landmark Study in The Lancet Oncology Shows Capecitabine (Xeloda(R)) Combination Therapy Reduces Early Breast Cancer Recurrence

Post Your Comments:

(Date:5/21/2013)... PARIS and TARRYTOWN, N.Y. ... and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) ... Medicine published online the positive Phase 2a study ... asthma. Dupilumab is an investigational monoclonal antibody targeting the ... which modulates signaling of both IL-4 and IL-13, drivers ...

(Date:5/21/2013)... U.S. spending on specialty prescription drugs — ... cancer, multiple sclerosis and rheumatoid arthritis — is projected ... according to a forecast released today by Express Scripts ... "As we see what,s on the ... act so they can continue to offer an affordable ...

(Date:5/21/2013)... , May 21, 2013 AcelRx ... a specialty pharmaceutical company focused on the ... the treatment of acute and breakthrough pain, ... a placebo-controlled Phase 3 study of its ... System (NanoTab System), the primary efficacy endpoint ...

Breaking Medicine Technology:Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 2 Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 3 Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 4 Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 5 Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 6 Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 7 U.S. Spending on Specialty Medications Likely to Increase 67 Percent Through 2015 2 U.S. Spending on Specialty Medications Likely to Increase 67 Percent Through 2015 3 U.S. Spending on Specialty Medications Likely to Increase 67 Percent Through 2015 4 U.S. Spending on Specialty Medications Likely to Increase 67 Percent Through 2015 5 Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 2 Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 3 Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 4 Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 5 Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 6 Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 7 Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 8 Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 9 Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 10

[0] Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine [0] U.S. Spending on Specialty Medications Likely to Increase 67 Percent Through 2015 [0] Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain

... Fla., Oct. 11, 2011 PediaVision announced today that ... United States to increase their efficiency and income through ... screening device that will help redefine the pediatric office ... pediatrics center in New Jersey, is a model of ...

... Heart disease is an ever-present threat in the family of ... experienced a heart attack in her early fifties. That,s why the ... Aspirin and WomenHeart: The National Coalition for Women with Heart ... Health to get women talking to each other and their ...

Cached Medicine Technology:Spot Helps Redefine the Pediatric Office of the Future 2 Spot Helps Redefine the Pediatric Office of the Future 3 Joy & Eve Behar Launch Bilingual Heart Health Guide Inspired By Women Heart Attack Survivors and Caregivers 2 Joy & Eve Behar Launch Bilingual Heart Health Guide Inspired By Women Heart Attack Survivors and Caregivers 3 Joy & Eve Behar Launch Bilingual Heart Health Guide Inspired By Women Heart Attack Survivors and Caregivers 4 Joy & Eve Behar Launch Bilingual Heart Health Guide Inspired By Women Heart Attack Survivors and Caregivers 5 Joy & Eve Behar Launch Bilingual Heart Health Guide Inspired By Women Heart Attack Survivors and Caregivers 6

Spot Helps Redefine the Pediatric Office of the Future Joy & Eve Behar Launch Bilingual Heart Health Guide Inspired By Women Heart Attack Survivors and Caregivers

(Date:5/21/2013)... HealthDay Reporter , , TUESDAY, May 21 (HealthDay News) -- ... to impossible, but a new study adds to a ... CT scans may help spot the beginnings of disease ... the greatest risk for lung cancer, 6 percent were ... and follow-up biopsies to confirm the diagnosis. CT scans ...

(Date:5/21/2013)... Sunnyvale, California (PRWEB) May 21, 2013 ... invites individuals who are grieving to remember and honor ... an Evening of Remembrance Memorial Service, Sunday, June 2, ... at Skyline Boulevard, San Mateo, CA 94402. , ... non-denominational, and includes a short program with music, readings ...

(Date:5/21/2013)... Calif. (PRWEB) May 21, 2013 Not ... a dual diagnosis of Borderline Personality Disorder (BPD) and ... is proving to be successful for the treatment of ... 1, Alina Gorgorian, Ph.D., clinical director of Clearview ... in Los Angeles, will provide attendees of the West ...

(Date:5/21/2013)... more likely than their normal-weight counterparts to repeatedly ... continuity of care and leads to more emergency ... The practice of "doctor shopping" among overweight patients ... the health care system, whether that be off-putting ... by providers, or improperly sized medical equipment and ...

(Date:5/21/2013)... N.C. An attack on glioblastoma brain tumor cells ... in an early study to establish the proper dose ... treatment, developed at Duke and tested in an ongoing ... cells have an abundance of receptors that work like ... the cells. , The investigational therapy, known as ...

Breaking Medicine News(10 mins):Health News:Study Supports Using Low-Dose CT Scans to Spot Early Lung Cancer 2 Health News:Study Supports Using Low-Dose CT Scans to Spot Early Lung Cancer 3 Health News:Hospice Offers Evening of Remembrance Memorial Service in San Mateo, California 2 Health News:Clearview Treatment Programs Clinical Director to Present on DBT and Substance Abuse at WCSAD 2 Health News:Clearview Treatment Programs Clinical Director to Present on DBT and Substance Abuse at WCSAD 3 Health News:'Doctor shopping' by obese patients negatively affects health 2 Health News:'Doctor shopping' by obese patients negatively affects health 3 Health News:Poliovirus vaccine trial shows early promise for recurrent glioblastoma 2

[0] Study Supports Using Low-Dose CT Scans to Spot Early Lung Cancer [0] Hospice Offers Evening of Remembrance Memorial Service in San Mateo, California [0] Clearview Treatment Programs Clinical Director to Present on DBT and Substance Abuse at WCSAD [0] 'Doctor shopping' by obese patients negatively affects health [0] Poliovirus vaccine trial shows early promise for recurrent glioblastoma

... makers debate what levels of ozone in the air are ... that the inhaled pollutant impairs the bodys first line of ... as bacteria. , While it has long been known ... pollution, is associated with increased cardiovascular and pulmonary hospitalizations and ...

... Programs in ... Need, BUDAPEST, Hungary, Sept. 29 With more ... each year, it has never,been more critical to increase ... the U.S.-Middle East Partnership for,Breast Cancer Awareness and Research, ...

... finds 123 deaths linked to the products since 1969 ... experts on Friday urged the federal Food and Drug ... and cold medicines for young children. , The recommendation, ... in children under 2, and antihistamines in those younger ...

... MCLEAN, Va., Sept. 28 Sunrise Senior Living,Inc. ... on the status of the independent,investigation being conducted ... Directors, provided an update on management,s Sarbanes-Oxley,Section 404 ... on legal,proceedings. Special Independent Committee Investigation ...

... a,statement by ADA President Kathleen Roth, DDS, on ... Bill: "The American Dental Association applauds the ... in legislation reauthorizing,the State Children,s Health Insurance Program. ... care that they need to enjoy good,oral health. ...

... Medical today announced a,partnership with leading breast care ... including breast care physicians from,Connecticut to California, will ... and availability of an innovative, non-surgical,treatment option for ... will host a gathering of these new Centers ...

Ozone shuts down early immune response in lungs and body Susan G. Komen for the Cure Launches Unprecedented Global Expansion Program in 10 Countries FDA Advisers Urge Ban on Cold Medicines for Young Children Sunrise Provides Status Report on Special Independent Committee Investigation; Provides Updates on Management's Internal Control Review Efforts and on Legal Proceedings Statement by ADA President Kathleen Roth, DDS, on the Inclusion of Stable Dental Benefit in SCHIP Reauthorization Bill Sanarus Announces Partnership With Leading US Breast Care Physicians for the Next Generation Visica 2(TM) Treatment System for Fibroadenomas

... 105SL combines enhanced memory, processing ... and reliable all-metal construction. Proven ... and print speed make it ... who value reliability, productivity, consistent ...

... Built on the solid, tested ... six-inch labels --offers an unprecedented level ... placement as well as unique features ... into enterprise systems, automatic calibration, flexible ...

... The 220XiIII quickly prints labels ... at 10 ips. It is ... such as printing chemical drum ... automotive industry labels, banner-sized labels ...

... The 140XiIII is the fastest ... Series. With such powerful performance and ... choice for high-volume, mission-critical applications with ... also well-suited for applications in which ...

Medicine Products:

105SL R170Xi Zebra Printer 220xiIII Zebra 140xiIII Barcode Printer